AccurKardia vs HeartSciences
If your failure mode is buying the HeartSciences name expecting HeartSciences' AI, read the regulatory line first. What a facility can purchase from HeartSciences in 2026 is an ECG reporting and management platform plus marketplace access to a third party's cleared model, from Bunkerhill Health, separately indexed here. Its own AI-ECG algorithms, for impaired cardiac relaxation and low ejection fraction, are not cleared and not commercially available. AccurKardia is the opposite: the algorithm is the entire product. Its AccurECG system holds two FDA 510(k) clearances, most recently a version 2.0 covering thirteen rhythm classifications in adults, and runs device agnostically across patches, Holter monitors, and telemetry. The honest split is availability. AccurKardia ships cleared interpretation today; HeartSciences ships the workflow and the distribution while its own models wait on the FDA.
- The algorithm is cleared and shipping today: two FDA 510(k) clearances, most recently version 2.0 under K252361 covering thirteen rhythm classifications in adults, which is regulator reviewed performance rather than a vendor claim.
- Device agnostic by design: it ingests ECG data from patches, Holter monitors, event recorders, and telemetry without custom integration, so a monitoring company or OEM can adopt without re platforming.
- An explicit no black box position with explainable output, which is the mechanism that makes the required physician over read meaningful rather than a rubber stamp.
- If you want a route to cleared AI-ECG for a smaller facility, the marketplace is the argument: it is positioned to bring cleared algorithms to community hospitals, critical access hospitals, and primary care, where cardiology reading is least available, starting with Bunkerhill's cleared ejection fraction model.
- It names the reimbursement pathway explicitly, assistive AI-ECG under the Hospital Outpatient Prospective Payment System at APC 5734, which lets a buyer model the revenue offset directly, something very few vendors here enable.
- It reports its own regulatory status candidly, separating device and algorithm submissions and explaining why, so a buyer is not misled about what is and is not cleared.
Side-by-Side
| Axis | A AccurKardia |
H HeartSciences |
|---|---|---|
| AI Centrality | ||
| Autonomy and Oversight Model | — | |
| Model and Technology Transparency | — | |
| Clinical and Operational Evidence | ||
| AI Safety and PHI Stewardship | — | |
| HIPAA and BAA Posture | — | |
| Security Certifications and Trust Center | — | |
| FDA and Regulatory Status | ||
| AI Governance and Bias Disclosure | — | |
| EHR and Interoperability Depth | — | |
| Deployment Model and Data Residency | — | |
| Commercial Transparency | ||
| Setting and Specialty Coverage |
The decisive fact is what each sells today. HeartSciences is graded C on AI centrality and FDA status because its own algorithms are not cleared or available; the cleared model in its marketplace belongs to Bunkerhill, and buying MyoVista Insights in 2026 means buying ECG workflow software plus access to someone else's model. AccurKardia carries the clearances but publishes no SOC 2, HIPAA, or PHI framework, which FDA clearance does not substitute for, and its 99 percent accuracy figure is vendor stated without peer reviewed prospective or head to head comparison against cardiologist over read. Its Breakthrough Device Designation for a hyperkalemia tool is an expedited review status, not a clearance.